Aurora Cannabis (ACB) Cash from Financing Activities (2017 - 2025)
Aurora Cannabis (ACB) posted quarterly Cash from Financing Activities of $1.3 million for Q4 2025, up 259.16% year-on-year from $348312.4 in Q4 2024, and up 226.32% on a QoQ basis from -$990318.3 in Q1 2025.
Aurora Cannabis (ACB) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Cash from Financing Activities for 9 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- Quarterly Cash from Financing Activities rose 259.16% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 138.95% YoY) and the FY2026 annual result came in at $3.5 million, up 211.42% from the prior year.
- Cash from Financing Activities grew to $1.3 million in Q4 2025 per ACB's latest filing, from -$990318.3 in the prior quarter.
- Over the last five years, Cash from Financing Activities for ACB reached as high as $129.9 million in Q1 2021 and fell as low as -$48.1 million in Q2 2021.
- A 5-year average of $12.5 million and a median of $232500.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities sank 1215.42% — and 2025, when it jumped 259.16%.
- Year by year, Cash from Financing Activities stood at -$5.9 million in 2021, then slumped by 680.38% to -$46.0 million in 2022, then jumped by 124.23% to $11.1 million in 2023, then plunged by 107.06% to -$786000.0 in 2024, then soared by 259.16% to $1.3 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.3 million, -$990318.3, and -$786000.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | -990,318.31 |
| Mar 31, 2025 | -990,318.31 |
| Dec 31, 2024 | -786,000.00 |
| Dec 31, 2024 | -786,000.00 |
| Sep 30, 2024 | 2.90 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | -4.61 Mn |
| Jun 30, 2024 | -4.61 Mn |
| Mar 31, 2024 | -3.62 Mn |
| Mar 31, 2024 | -3.62 Mn |
| Dec 31, 2023 | 11.13 Mn |
| Dec 31, 2023 | 11.13 Mn |
| Sep 30, 2023 | 2.79 Mn |
| Sep 30, 2023 | 2.79 Mn |
| Dec 31, 2022 | -45.96 Mn |
| Dec 31, 2022 | -45.96 Mn |
| Sep 30, 2022 | 40.18 Mn |
| Sep 30, 2022 | 40.18 Mn |